Tag: Catheter Ablation
-
DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation
New Findings Question SGLT2 Inhibitors for Post-Ablation AF Recurrence In a development that surprises many in the cardiology community, the DARE-HF trial examined whether the SGLT2 inhibitor dapagliflozin could reduce the burden of atrial fibrillation (AF) after catheter ablation. Conducted in patients who recently underwent ablation for AF, the study aimed to determine if adding…
-
DARE-AF: Dapagliflozin Fails to Reduce AF Recurrence After Catheter Ablation
Overview: DARE-AF Trial Questions SGLT2 Inhibition After Ablation The latest findings from the DARE-AF trial suggest that dapagliflozin, an SGLT2 inhibitor, does not reduce the burden of atrial fibrillation (AF) after catheter ablation. Conducted in a diverse patient population, the study aimed to determine whether adding dapagliflozin to standard post-ablation care could lower AF recurrence…
-
DARE-AF Trial: Dapagliflozin Fails to Reduce AF Burden After Ablation
Overview: Aiming to Lower AF Recurrence With SGLT2 Inhibition The DARE-HF trial, conducted in New Orleans, tested whether dapagliflozin, an SGLT2 inhibitor, could reduce the burden of atrial fibrillation (AF) after catheter ablation. AF remains a leading heart rhythm disorder, and recurrence after ablation poses a persistent challenge for patients and clinicians. While SGLT2 inhibitors…